Skip to content
type1.science
ObservationalRecruitingNCT06891898

iLet Experience real-world safety and effectiveness study

Beta Bionics prospective real-world cohort collecting one-year safety and effectiveness data for the iLet Dosing Decision Software in people aged 6 and older with type 1 diabetes.

Primary endpoints

  • Severe hypoglycemia or cognitive impairment over 1 year

Results so far

No results posted yet.